Mexico The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents more than 60 of the country’s research-based pharmaceutical companies. Executive director Larry Rubin, who took on the association’s leadership six months ago, outlines his priorities, such as building public awareness and stronger relationships with the government. He also weighs in on…
Mexico Gilead’s Mexican affiliate is its largest in the LatAm region, and one that has had an impressive impact as 85 percent of those living with HIV in the country are treated with the company’s therapies. With just seven months behind him as GM, Arturo de la Rosa explains what is…
Mexico Vincenzo D’Elia discusses the creation of Alfasigma’s Mexican affiliate – now solidly established after 14 years – and the company’s local strategy and market approach. He emphasizes the importance of understanding market dynamics for localized portfolio selection, highlights the company’s decision not to engage in government contracts, and comments on…
Mexico Adium Mexico, recently rebranded to reflect the identity of the broader Adium Group, represents no less than 25 percent of the LatAm group’s sales. General Director José Miguel Fonken Quiroga shares the affiliate’s number one status, stellar growth, vast portfolio, and plans to expand into OTC and vaccines. Fonkel also…
Mexico This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In some cases, the appointments represent a first for affiliates that have never had female leaders while in others they coincide…
LatAm A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s acquisition of 30% of Argentina’s Tuteur, and Urufarma’s new manufacturing facility in Uruguay. Merck to open new distribution centre…
Mexico Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will also mark another historic first as the two leading presidential hopefuls are women: Claudia Sheinbaum of the incumbent president Andres…
LatAm Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s fundamentals as a research hotspot, and the strategies in place to bolster its global positioning. Clinical trials in Latin…
LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…
Global After gaining its first global approval in Indonesia, Takeda’s dengue fever vaccine, Qdenga, recently got a green light from the European Commission (EC) to market the vaccine in Europe, laying the foundation for further approvals in dengue-endemic regions like Latin America. We are one step closer to achieving our aspiration…
Americas Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also…
Mexico Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are extending their footprint into LatAm. Grupo Sanfer/Hormona Mexico has already taken up positions across the region. Laboratorios Sanfer, founded…
See our Cookie Privacy Policy Here